Literature DB >> 25016220

Thyrotropin increases hepatic triglyceride content through upregulation of SREBP-1c activity.

Fang Yan1, Qi Wang2, Ming Lu1, Wenbin Chen3, Yongfeng Song1, Fei Jing1, Youfei Guan4, Laicheng Wang3, Yanliang Lin3, Tao Bo3, Jie Zhang3, Tingting Wang5, Wei Xin3, Chunxiao Yu1, Qingbo Guan1, Xinli Zhou1, Ling Gao6, Chao Xu7, Jiajun Zhao8.   

Abstract

BACKGROUND & AIMS: Hallmarks of non-alcoholic fatty liver disease (NAFLD) are increased triglyceride accumulation within hepatocytes. The prevalence of NAFLD increases steadily with increasing thyrotropin (TSH) levels. However, the underlying mechanisms are largely unknown. Here, we focused on exploring the effect and mechanism of TSH on the hepatic triglyceride content.
METHODS: As the function of TSH is mediated through the TSH receptor (TSHR), Tshr(-/-) mice (supplemented with thyroxine) were used. Liver steatosis and triglyceride content were analysed in Tshr(-/-) and Tshr(+/+) mice fed a high-fat or normal chow diet, as well as in Srebp-1c(-/-) and Tshr(-/-)Srebp-1c(-/-) mice. The expression levels of proteins and genes involved in liver triglyceride metabolism was measured.
RESULTS: Compared with control littermates, the high-fat diet induced a relatively low degree of liver steatosis in Tshr(-/-) mice. Even under chow diet, hepatic triglyceride content was decreased in Tshr(-/-) mice. TSH caused concentration- and time-dependent effects on intracellular triglyceride contents in hepatocytes in vitro. The activity of SREBP-1c, a key regulator involved in triglyceride metabolism and in the pathogenesis of NAFLD, was significantly lower in Tshr(-/-) mice. In Tshr(-/-)Srebp-1c(-/-) mice, the liver triglyceride content showed no significant difference compared with Tshr(+/+)Srebp-1c(-/-) mice. When mice were injected with forskolin (cAMP activator), H89 (inhibitor of PKA) or AICAR (AMPK activator), or HeG2 cells received MK886 (PPARα inhibitor), triglyceride contents presented in a manner dependent on SREBP-1c activity. The mechanism, underlying TSH-induced liver triglyceride accumulation, involved that TSH, through its receptor TSHR, triggered hepatic SREBP-1c activity via the cAMP/PKA/PPARα pathway associated with decreased AMPK, which further increased the expression of genes associated with lipogenesis.
CONCLUSIONS: TSH increased the hepatic triglyceride content, indicating an essential role for TSH in the pathogenesis of NAFLD.
Copyright © 2014 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Hepatic steatosis; Peroxisome proliferator-activated receptor α; Sterol regulatory element-binding protein 1c; Thyrotropin (TSH); Triglyceride

Mesh:

Substances:

Year:  2014        PMID: 25016220     DOI: 10.1016/j.jhep.2014.06.037

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  32 in total

1.  Desensitization and Incomplete Recovery of Hepatic Target Genes After Chronic Thyroid Hormone Treatment and Withdrawal in Male Adult Mice.

Authors:  Kenji Ohba; Melvin Khee-Shing Leow; Brijesh Kumar Singh; Rohit Anthony Sinha; Ronny Lesmana; Xiao-Hui Liao; Sujoy Ghosh; Samuel Refetoff; Judy Chia Ghee Sng; Paul Michael Yen
Journal:  Endocrinology       Date:  2016-02-11       Impact factor: 4.736

Review 2.  Relationship between the development of hyperlipidemia in hypothyroidism patients.

Authors:  Xin Su; Xiang Chen; Bin Wang
Journal:  Mol Biol Rep       Date:  2022-09-12       Impact factor: 2.742

3.  Severe Phenotype of Non-alcoholic Fatty Liver Disease in Pediatric Patients with Subclinical Hypothyroidism: a Retrospective Multicenter Study from Korea.

Authors:  So Yoon Choi; Dae Yong Yi; Soon Chul Kim; Ben Kang; Byung Ho Choe; Yoon Lee; Yoo Min Lee; Eun Hye Lee; Hyo Jeong Jang; You Jin Choi; Hyun Jin Kim
Journal:  J Korean Med Sci       Date:  2021-05-24       Impact factor: 2.153

Review 4.  Unraveling the Role of Hypothyroidism in Non-alcoholic Fatty Liver Disease Pathogenesis: Correlations, Conflicts, and the Current Stand.

Authors:  Rajvi Gor; Nabeel A Siddiqui; Ransirini Wijeratne Fernando; Archana Sreekantan Nair; Janan Illango; Mushrin Malik; Pousette Hamid
Journal:  Cureus       Date:  2021-05-05

5.  Endoplasmic Reticulum Stress May Play a Pivotal Role in Lipid Metabolic Disorders in a Novel Mouse Model of Subclinical Hypothyroidism.

Authors:  Lingyan Zhou; Shuyan Ding; Yujie Li; Laicheng Wang; Wenbin Chen; Tao Bo; Kunpeng Wu; Congcong Li; Xiaojing Liu; Jiajun Zhao; Chao Xu; Ling Gao
Journal:  Sci Rep       Date:  2016-08-19       Impact factor: 4.379

6.  Both 3,5-Diiodo-L-Thyronine and 3,5,3'-Triiodo-L-Thyronine Prevent Short-term Hepatic Lipid Accumulation via Distinct Mechanisms in Rats Being Fed a High-Fat Diet.

Authors:  Rosalba Senese; Federica Cioffi; Pieter de Lange; Cristina Leanza; Liliana F Iannucci; Elena Silvestri; Maria Moreno; Assunta Lombardi; Fernando Goglia; Antonia Lanni
Journal:  Front Physiol       Date:  2017-09-14       Impact factor: 4.566

7.  Benefits of Levothyroxine Replacement Therapy on Nonalcoholic Fatty Liver Disease in Subclinical Hypothyroidism Patients.

Authors:  Lu Liu; Yong Yu; Meng Zhao; Dongmei Zheng; Xu Zhang; Qingbo Guan; Chao Xu; Ling Gao; Jiajun Zhao; Haiqing Zhang
Journal:  Int J Endocrinol       Date:  2017-04-04       Impact factor: 3.257

Review 8.  Nonalcoholic Fatty Liver Disease and Hypercholesterolemia: Roles of Thyroid Hormones, Metabolites, and Agonists.

Authors:  Rohit A Sinha; Eveline Bruinstroop; Brijesh K Singh; Paul M Yen
Journal:  Thyroid       Date:  2019-09       Impact factor: 6.568

Review 9.  Direct effects of thyroid hormones on hepatic lipid metabolism.

Authors:  Rohit A Sinha; Brijesh K Singh; Paul M Yen
Journal:  Nat Rev Endocrinol       Date:  2018-02-23       Impact factor: 43.330

10.  Serum fibroblast growth factor 19 is decreased in patients with overt hypothyroidism and subclinical hypothyroidism.

Authors:  Yaxin Lai; Haoyu Wang; Xinghai Xia; Zhaojun Wang; Chenling Fan; Hong Wang; Hongmei Zhang; Shuangning Ding; Weiping Teng; Zhongyan Shan
Journal:  Medicine (Baltimore)       Date:  2016-09       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.